High Risk - High Reward

Nano-X Imaging (NNOX) went public in the second half of 2020 and has been on a rollercoaster of a ride. The Israeli company purchased imaging technology in 2012 from Sony, and is planning to produce a new imaging device with a much smaller footprint and lower price than a tradition x-ray machine. The produced images are fully digital and the company uses it’s own software, which can be combined with other artificial intelligence technologies to potentially improve diagnosis and further aid clinical imaging analysis. For investors this is especially compelling since the company is planning on making this a subscription model with a charge per image - similar to a SAAS software model. Nano-x is even planning on giving the machine to hospitals for free, in jurisdictions where that’s legal, and profiting on the per image subscription fee.

Founder and Backers

The founder and CEO Ran Poliakine has a long track record of starting successful companies, which include: Powermat, Wellsense, Years of Water, QinFlow, Illumigyn, Tap Systems, SixAI, Musashi AI

Polakine’s largest other company, Powermat Technologies, has become one of the two major wireless charging formats which has been adopted by AT&T, Duracell, Starbucks, Flextronics,Energy Star.

Nano-X also has secured partnerships with Foxconn Technology Group for manufacturing and Fujifilm, a veteran of the imaging space. It’s also received a large investment from South Korea Telecom.


This company does not yet have an approved device or any real revenue. Investing in such an early phase company naturally carries a lot of risk. The recent run up has also expanded their market cap to over 2 billion, and with all of it’s volatility there may be pullbacks ahead.

Shortly after the IPO the stock ran up over $60 a share, but a short seller report targeted the company which pushed the stock price back down closer to where it initially IPOed. However, the announcement of the demo(see catalysts below), has re-assured some worried investors of the alleged concerns and has helped the stock rebound.


The stock has three catalysts which are helping drive up the stock price

  1. Thursday December 3rd 2020 - Live demo of the Nano-X Arc at the Radiology Society of North America 2020 virtual conference. This is especially important to refudiate the claims of the short sellers.
  2. Any week - FDA 510(K) application in for a single-source device which could get approved before 1H 2021.
  3. Mid-year 2021 - FDA 510(K) approval of the multi-source device, the one planned on being commercialized. This one is the bigger deal and is needed to drive revenue.

The FDA approvals get updated weekly at 1AM (EST) each Monday and can be found here.

This site references only our opinion and is for information purposes only. It is not intended to be investment advice. Seek a duly licensed professional for investment advice.

Rule of 40 - November 2020

With so many tech stocks running hot, it's worth taking a look at the Rule of 40. The Rule of 40 is one way to analyze tech companies, especially SAAS (software as a service) companies, to check if their growth rate combined with their profitability is enough to warrant a premium valuation.

The Rule of 40 is calculated by adding the revenue growth rate and profit. The profit is usually calculated with Free Cash Flow Margin or EBITDA. When a company is in hyper-growth mode it's prudent to fund rapid growth and for the time being run at a deficit or a meager profit. However, it can be problematic if the company isn't growing fast enough, and doesn't have a sizeable profit yet either. The Rule of 40 can help us quickly measure this. The higher the number, the better. The rule of thumb is that a number higher than 40, meets this criteria.

Measuring Valuation

While the Rule of 40 is a useful tool to measure the growth vs profit, it doesn’t tell us anything about the current valuation. One other method is to check the PS Ratio (price to sales), if it is 5 times less than the Rule of 40 score, then it’s often considered a good value.

For an even better insight, you can divide the Rule of 40 score by the PS ratio. The higher the number, the better the growth and profit is relative to the price of the stock.

We ran a few examples using data from gurufocus. The below list is ranked by the highest Rule of 40/PS score. TWOU, ETSY, SE, MELI, CHGG appear to be the winners here.


Symbol PS Ratio 1-Year Total Revenue Growth Rate FCF Margin % Rule of 40 Rule of 40/PS
TWOU 2.98 37.2 -5.75 31.45 10.55
ETSY 15.28 84.2 36.76 120.96 7.92
SE 24.08 113.3 8.14 121.44 5.04
MELI 22.66 62 24.34 86.34 3.81
CHGG 16.78 48 13.75 61.75 3.68
ESTC 20.81 53.2 -2.3 50.90 2.45
ROKU 22.3 55 -2.08 52.92 2.37
ZM 103.49 190.4 52.34 242.74 2.35
CRWD 48.69 86.4 27.07 113.47 2.33
TEAM 32.46 30.9 31.58 62.48 1.92
TWLO 29.3 53.3 -3.05 50.25 1.72
WORK 29.4 51.4 -1.04 50.36 1.71
SHOP 49.58 75 7.46 82.46 1.66
FVRR 42.01 66.1 3.75 69.85 1.66
DDOG 56.15 73.6 14.35 87.95 1.57
DOCU 35.49 40.6 11.51 52.11 1.47
OKTA 41.22 44.6 9.09 53.69 1.30
MDB 30.88 45 -8.64 36.36 1.18
FSLY 31.25 46.5 -10.48 36.02 1.15
PINS 29.41 36.5 -6.47 30.03 1.02
TTD 57.93 20.9 18.08 38.98 0.67
NET 57.56 50.5 -23.69 26.81 0.47
APPN 45.4 15.7 -7.38 8.32 0.18
SPLK 13.56 14.6 -18.26 -3.66 -0.27

Valuation Course: An Introductory Course to Measuring the Value of Companies (Wiley Finance)

This site references only our opinion and is for information purposes only. It is not intended to be investment advice. Seek a duly licensed professional for investment advice

Booking Holdings

Booking Over Extended on Vaccine News

The vaccine news has quickly lead to a large rebound in virtually every COVID recovery, “value”, travel stock. However, with the pandemic numbers rising to unprecedented levels some stocks in particular have seemingly gotten ahead of themselves.

This is especially true for travel stocks. Today we’re looking at Booking Holdings (BKNG). Booking operates, KAYAK, priceline, agoda,, and OpenTable. BKNG has been historically a great company with a strong balance sheet and great returns over the past decade. While we’re bullish on BKNG over the long term, and think it is likely it will come out of the current pandemic and rebuild it’s strength and continue to grow over the coming years, it’s very difficult to see how now it should continue trading at 52 weeks highs, and just a few percent of all time highs given the current climate. A vaccine is great news, but the travel will continue being largely a troubled industry for a minimum of another couple of quarters.

As you can imagine with any travel stock, the past couple of quarters have been challenging ones - yet the stock is now at 52 weeks highs.

Prior to this week, it’s previous 52 high close week was 2,080.50 on January 13th, 2020.
It’s all time high 2206.09 was over two years ago on March 12, 2018.

On November 9th it reached a high of 2,128.02 but closed below that.

We’re entering a trade where we think this will begin reverting to the mean once the vaccine euphoria settles. For this trade we’ve entered a call credit spread. Here we’re selling the 12/11 $2120 call and buying the 12/11 $2140 call.

  • Sell 12/11 $2140 call
  • Buy 12/11 $2120 call

Net credit/max gain: $900
Maximum loss: $1100

With a credit spread, your hope is that both options expire worthless and you get to keep the premium. If the thesis is correct, the closer to expiration the option is and the lower the stock price is, the more the value of spread decreases. Assuming it finishes below 2110, the calls expire worthless and the premium is kept either way.

If BKNG goes beyond these levels, depending on risk tolerance, it’s possible to roll out the spread out in time, expand the width and increase the strike prices.

This site references only our opinion and is for information purposes only. It is not intended to be investment advice. Seek a duly licensed professional for investment advice. Disclosure: we are net short BKNG with call credit spreads.